Leukemia research最新文献_第2页

Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-06 DOI: 10.1016/j.leukres.2025.107661

Kensuke Takaoka , Rami Komrokji , Kelly Chien , Guillermo Montalban-Bravo , Julie Braish Salman , Samuel Urrutia , Alex Bataller , Alexandre Bazinet , Jeannot Kekedjian , Najla H. Al Ali , David Sallman , Eric Padron , Zhuoer Xie , Rashmi Kanagal-Shamanna , Guilin Tang , Hui Yang , Juan Jose Rodriguez-Sevilla , Guillermo Garcia-Manero , Koji Sasaki

{"title":"Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion","authors":"Kensuke Takaoka , Rami Komrokji , Kelly Chien , Guillermo Montalban-Bravo , Julie Braish Salman , Samuel Urrutia , Alex Bataller , Alexandre Bazinet , Jeannot Kekedjian , Najla H. Al Ali , David Sallman , Eric Padron , Zhuoer Xie , Rashmi Kanagal-Shamanna , Guilin Tang , Hui Yang , Juan Jose Rodriguez-Sevilla , Guillermo Garcia-Manero , Koji Sasaki","doi":"10.1016/j.leukres.2025.107661","DOIUrl":"10.1016/j.leukres.2025.107661","url":null,"abstract":"<div><div>Myelodysplastic syndrome (MDS) with isolated deletion 11q is a rare favorable cytogenetic abnormality with a low risk of progression to acute myeloid leukemia (AML). The aim of this study is to describe the clinical characteristics and long-term outcomes of patients with isolated del(11q) MDS. Between August 1997 and January 2024, 52 patients with MDS and isolated del(11q) were diagnosed, representing 0.4 % of the cohort. The median age was 69 years, with a mild male predominance (62 %). By the World Health Organization (WHO) 2022, 42 % of patients had MDS with low blasts. With a median follow-up of 96 months, the median survival was 71 months with a 5-year survival rate of 53 %. The 5-year survival rates were 45 % and 68 % in the hypomethylating agents and best supportive care group, respectively (P = 0.63). Multivariate Cox regression analyses identified age, absolute neutrophil count, hemoglobin, and blast percentages as significant prognostic factors. Despite isolated del(11q) MDS being classified as a very-good-risk cytogenetic abnormality, long-term survival is poor with the risk of progression to AML and complications from cytopenias. The poor long-term survival indicates the need for the investigation of effective supportive care and early intervention to benefit patients with lower-risk MDS and high-risk features.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"150 ","pages":"Article 107661"},"PeriodicalIF":2.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-04 DOI: 10.1016/j.leukres.2025.107662

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Alison Walker, Jeffrey Lancet, Andrew Kuykendall, David Sallman, Eric Padron, Rami S. Komrokji

{"title":"Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),","authors":"Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Alison Walker, Jeffrey Lancet, Andrew Kuykendall, David Sallman, Eric Padron, Rami S. Komrokji","doi":"10.1016/j.leukres.2025.107662","DOIUrl":"10.1016/j.leukres.2025.107662","url":null,"abstract":"<div><div>CMML is a heterogenous myelodysplastic/myeloproliferative neoplasm (MDS/MPN) sharing both diseases' molecular and clinical phenotypes. Several models are used to risk-stratify patients diagnosed with CMML. Inflammation plays a pivotal role in developing the disease or its progression and has been linked to worse outcomes. Serum albumin (SA) is an inflammatory marker and/or surrogate for co-morbidities. While the role of SA has been investigated in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), multiple myeloma, and other cancers, its prognostic value in CMML remains unclear. We identified 919 patients diagnosed with CMML with known SA levels at the time of diagnosis or prior to any therapy. We divided patients into three groups based on SA levels: < 3.5 g/dL, 3.5–4.0 g/dL and > 4.0 g/dL. We then compared the baseline characteristics and outcomes of these three groups. Patients with SA < 3.5 g/dL had higher risk disease according to the CPSS-Molecular model, WHO 2022 classification, and FAB classification. Additionally, patients with SA < 3.5 g/dL had a higher median blast percentage, ferritin levels, WBC, and monocyte count (P < 0.001). These patients were also more likely to be cytopenic and RBC transfusion-dependent (RBC-TD) (P < 0.001). In multivariable Cox regression analysis, SA was independently significant for predicting overall survival (OS) after adjusting for CPSS-Molecular risk, WHO 2022 subtype, proliferative CMML (FAB classification), RBC-TD, and bi/pancytopenia. Therefore, SA is an independent prognostic factor for OS among patients with CMML. Low SA may reflect inflammatory disease status or a surrogate for co-morbidities. Risk stratification models should incorporate serum albumin levels to refine their prognostic value.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"150 ","pages":"Article 107662"},"PeriodicalIF":2.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway Anlotinib通过抑制P13K/AKT信号通路增强APG-115对急性髓系白血病细胞的促凋亡作用。

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2024.107637

Rui Zhao , Yu Cui , Dongbei Li , Xiaoli Guo , Cheng Cheng , Rongheng He , Chenxi Hu , Xudong Wei

{"title":"Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway","authors":"Rui Zhao , Yu Cui , Dongbei Li , Xiaoli Guo , Cheng Cheng , Rongheng He , Chenxi Hu , Xudong Wei","doi":"10.1016/j.leukres.2024.107637","DOIUrl":"10.1016/j.leukres.2024.107637","url":null,"abstract":"<div><h3>Background</h3><div>APG-115 is a novel small-molecule selective inhibitor that destabilizes the p53-MDM2 complex and activates p53-mediated apoptosis in tumor cells. Anlotinib inhibits tumor angiogenesis and promotes apoptosis. In this study, we investigated the apoptotic effect and potential mechanism of APG-115 and anlotinib combination on AML cell lines with different p53 backgrounds.</div></div><div><h3>Material and methods</h3><div>The IC50 values of APG-115 and anlotinib were detected by CCK-8 assay. The apoptosis rate of AML cells was evaluated by Annexin-V and PI double staining. Transcriptome sequencing was performed on the MOLM16 cell line treated with APG-115 and anlotinib, and differential analysis and enrichment analysis were performed. Real-time quantitative PCR and Western blot were used to detect the changes in cell cycle and pathway-related genes and proteins in AML cell lines after drug treatment. In <em>vivo</em> experiments, the anti-leukemia effects of APG-115 and anlotinib on AML xenograft mouse models were evaluated.</div></div><div><h3>Results</h3><div>APG-115 and anlotinib could independently promote AML cell apoptosis, and the combination of the two drugs could produce a synergistic effect. Transcriptome sequencing showed that compared with the APG-115 monotherapy group, the differentially expressed genes were mainly enriched in the MDM2-p53 and PI3K/AKT pathways. In <em>vivo</em> experiments showed that compared with AML xenograft mice treated with either drug alone, AML progression was slowed in AML xenograft mice treated with APG-115 and anlotinib.</div></div><div><h3>Conclusion</h3><div>In <em>vivo</em> and in <em>vitro</em> experimental have shown that APG-115 combined with anlotinib can promote AML cells apoptosis and inhibit the progression of disease is independent of the p53 status.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107637"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma 自体干细胞移植后克隆同型开关的存在作为多发性骨髓瘤患者长期生存的预后生物标志物

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2025.107641

Hanwool Cho , Jinhang Kim , Youngrok Park , Bo-Hee Lee , Misuk Yang , Yeongsic Kim , Jeong-A Kim

{"title":"The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma","authors":"Hanwool Cho , Jinhang Kim , Youngrok Park , Bo-Hee Lee , Misuk Yang , Yeongsic Kim , Jeong-A Kim","doi":"10.1016/j.leukres.2025.107641","DOIUrl":"10.1016/j.leukres.2025.107641","url":null,"abstract":"<div><div>Clonal isotype switch (CIS) in multiple myeloma (MM) refers to the emergence of new immunoglobulin bands distinct from those present at diagnosis. CIS often appears after high-dose chemotherapy and autologous stem cell transplantation (ASCT), reflecting post-transplant immune recovery. However, its prognostic significance remains unclear. In this study, CIS was observed (CIS-positive) in 31.7 % (26/82) of patients undergoing ASCT. Patients receiving bortezomib-containing induction therapy showed a higher prevalence of CIS compared to those treated with vincristine-doxorubicin-dexamethasone chemotherapy (37.9 % vs. 16.7 %, p = 0.061). Median overall survival (OS) was not estimable (NE) in the CIS-positive group, while it was 47 months in the CIS-negative group (hazard ratio [HR]: 0.27, 95 % CI: 0.11–0.67; p = 0.005). Median progression-free survival (PFS) was also NE in the CIS-positive group versus 26 months in the CIS-negative group (HR: 0.25, 95 % CI: 0.11–0.58; p = 0.001). These findings suggest that CIS is an independent biomarker associated with favorable outcomes in MM patients undergoing ASCT.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107641"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas 弥漫性大B细胞淋巴瘤临床预后因素、微血管密度、肿瘤浸润淋巴细胞与CD47、SIRPα表达的关系

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2024.107636

Aydan Kılıçarslan , Sevdenur Özdüzgün Polat , Hayriye Tatlı Doğan , Tuğba Dilay Kökenek Ünal , Şefika Karabulut , Gülsüm Özet

{"title":"The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas","authors":"Aydan Kılıçarslan , Sevdenur Özdüzgün Polat , Hayriye Tatlı Doğan , Tuğba Dilay Kökenek Ünal , Şefika Karabulut , Gülsüm Özet","doi":"10.1016/j.leukres.2024.107636","DOIUrl":"10.1016/j.leukres.2024.107636","url":null,"abstract":"<div><div>CD47 interacts with signal regulatory protein alpha (SIRPα) on macrophages to deliver an anti-phagocytic signal, enabling tumor cells to evade immune destruction. This study explores the relationship between CD47 and SIRPα expression and key clinical prognostic factors, microvascular density (MVD), and tumor-infiltrating lymphocytes (TIL) in Diffuse Large B Cell Lymphoma (DLBCL) cases. We analyzed tissue samples from 122 DLBCL cases using tissue microarray (TMA) blocks and immunohistochemical staining for CD47, SIRPα, CD31, and CD3. CD47 expression was scored using the Allred scoring system, and SIRPα expression was quantified based on the percentage of positive membranous and cytoplasmic expression. Clinical data, including IPI scores, relapse rates, and gene expression profiles, were correlated with the immunohistochemical findings.CD47 expression score ≥ 6 was significantly associated with the DLBCL-ABC phenotype (p = 0.029), higher IPI scores (p = 0.020), and increased relapse rates (p = 0.021). High SIRPα expression (≥25 % staining) was also linked to the ABC phenotype (p = 0.022) and frequent relapses (p = 0.021). Notably, cases with high microvascular density exhibited lower SIRPα expression (p = 0.013). There was no significant relationship between MVD and CD47 or other clinical prognostic factors. Additionally, higher CD3-positive TIL percentages were inversely correlated with IPI scores (p = 0.005), although no significant association was found between CD3 and CD47-SIRPα. The study reveals that increased CD47-SIRPα expression is partially linked to adverse prognostic indicators and reduced MVD in DLBCL cases. These findings suggest that targeting the CD47-SIRPα axis could offer a novel therapeutic approach in DLBCL, particularly for patients with poor prognostic features.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107636"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia 探讨MDM2基因启动子变异在慢性髓性白血病中的意义。

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2025.107644

María Belén Fontecha , María del Rosario Anadón , Inés María Martínez Lahitou , Natalia Weich , Raquel Bengió , Beatriz Moiraghi , Irene Larripa , Ariela Freya Fundia

{"title":"Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia","authors":"María Belén Fontecha , María del Rosario Anadón , Inés María Martínez Lahitou , Natalia Weich , Raquel Bengió , Beatriz Moiraghi , Irene Larripa , Ariela Freya Fundia","doi":"10.1016/j.leukres.2025.107644","DOIUrl":"10.1016/j.leukres.2025.107644","url":null,"abstract":"<div><div>Tyrosine kinase inhibitors (TKIs) targeting <em>BCR::ABL1</em> are highly successful in chronic myeloid leukemia (CML). However, extensive interpatient variability in therapeutic responses and resistance supports the need to find new prognostic biomarkers. We have previously reported that <em>TP53</em> SNP215 variant affects CML risk and clinical outcome. We aimed to evaluate the role of <em>MDM2</em> genetic variants in CML susceptibility and treatment response to TKIs. We genotyped five <em>MDM2</em> promoter variants (del1518, SNP309, SNP285, SNP288 and SNP344) in 135 CML patients and 136 healthy individuals. Our study showed that <em>MDM2</em> variants alone or in combination had no effect on CML susceptibility. The analysis of <em>MDM2</em> genotypes in relation to patients’ clinical parameters revealed that individuals with SNP309 G/G genotypes were at a significantly increased risk of undergoing molecular response failure (p = 0.044). Improved overall survival was also observed for non-responders with the alternative <em>MDM2</em> del1518 del allele (p = 0.017) as well as for <em>MDM2</em> del1518-SNP309 combinations with alternative genotypes (p = 0.014). In addition, combinatorial analysis demonstrated that alternative <em>MDM2</em> SNP309 and <em>TP53</em> SNP215 genotypes together are associated with faster achievement of MR<sup>2</sup> (p = 0.029) and MMR (p = 0.042) in non-responders, suggesting a relationship with a favorable outcome. Overall, our study highlights the influence of <em>MDM2</em> variants on clinical outcome, supporting that specific genotypes, alone or in combination, underlie the treatment-responsive phenotype.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107644"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New treatments for adult T-cell leukemia/lymphoma

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2025.107642

Zachary D. Epstein-Peterson , Ashwath Gurumurthi , Steven M. Horwitz

{"title":"New treatments for adult T-cell leukemia/lymphoma","authors":"Zachary D. Epstein-Peterson , Ashwath Gurumurthi , Steven M. Horwitz","doi":"10.1016/j.leukres.2025.107642","DOIUrl":"10.1016/j.leukres.2025.107642","url":null,"abstract":"<div><div>Adult T cell leukemia lymphoma (ATL) is a mature T cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1). ATL is endemic in specific geographic regions of the world closely related to areas with high prevalence of HLTV-1 infection, including Southwestern Japan, the Caribbean Basin, Central Africa, South America, Northern and Central Australia. HLTV-1 is primarily transmitted through breastmilk in asymptomatic carriers with a long latency period before transformation into ATL in 3 – 5 % of carriers after acquisition of multiple leukemogenic mutations. The Shimoyama classification established by the Japanese Lymphoma Study Group more than three decades ago remains clinically relevant and practical for guiding treatment. Due to the rarity of this illness, prospective, large prospective clinical are challenging to perform and treatment recommendations are based upon limited evidence. Aggressive disease subtypes have median survival ranging in months and the only curative therapy remains achieving deep remission with induction therapy followed by consolidative allogeneic transplantation. The prognosis for relapsed disease remains dismal due to chemo-refractoriness and limited therapeutic options. Herein, we review the current landscape of novel therapeutic agents with a focus on relapsed and refractory ATL including their mechanisms of action, resistance, and clinical efficacy.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107642"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel KMT2A::DCP1A fusion gene in acute myeloid leukemia 一种新的KMT2A::DCP1A融合基因在急性髓性白血病中的应用。

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2025.107645

Ailing Deng , Fenghong Zhang , Man Wang, Dongyun Jiang, Jiannong Cen, Mengxing Xue, Yun Wang, Xueqing Dou, Qian Wu, Xiaofei Yang, Suning Chen

引用次数: 0

Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma 靶向抗体治疗作为侵袭性成人t细胞白血病/淋巴瘤的治疗策略

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2025.107653

Makoto Yoshimitsu

引用次数: 0

Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial zimberelimab治疗复发或难治性经典霍奇金淋巴瘤的长期随访：来自ⅡYH-S001-04期临床试验的见解

IF 2.1 4区医学

Leukemia research Pub Date : 2025-02-01 DOI: 10.1016/j.leukres.2024.107633

Suisui Kan , Hai Bai , Hui Liu , Jie Cui , Xiaoyan Ke , Huilai Zhang , Lihong Liu , Dongmei Yan , Yongsheng Jiang , Aimin Zang , Junyuan Qi , Li Wang , Zhuogang Liu , Bing Xu , Ying Zhang , Zhihui Zhang , Xielan Zhao , Chunhong Hu , Shenmiao Yang , Hui Zhou , Mingzhi Zhang

{"title":"Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial","authors":"Suisui Kan , Hai Bai , Hui Liu , Jie Cui , Xiaoyan Ke , Huilai Zhang , Lihong Liu , Dongmei Yan , Yongsheng Jiang , Aimin Zang , Junyuan Qi , Li Wang , Zhuogang Liu , Bing Xu , Ying Zhang , Zhihui Zhang , Xielan Zhao , Chunhong Hu , Shenmiao Yang , Hui Zhou , Mingzhi Zhang","doi":"10.1016/j.leukres.2024.107633","DOIUrl":"10.1016/j.leukres.2024.107633","url":null,"abstract":"<div><h3>Background</h3><div>Treating relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging. This report extends the three-year follow-up period for the phase Ⅱ YH-S001–04 trial, expanding upon the initial 15.8-month analysis.</div></div><div><h3>Methods</h3><div>Zimberelimab 240 mg was administered every two weeks for two years or until disease progression or death. The endpoint was the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>The median follow-up was 38.0 months (3.5–42.8 months). The ORR was 91.6 % (95 % CI, 83.8–95.9). Median PFS was 23.6 months, with a longer PFS in responders (28.5 months) compared to non-responders (9.2 months) (<em>P</em>=0.0098). Complete responders had longer mPFS than partial responders (Not reached vs. 28.5 months, <em>P</em>=0.3469). Relapsed patients had improved mPFS compared to refractory cHL (23.6 vs. 10.6 months, <em>P</em>=0.0061). Patients with ＜3 lines of therapy showed longer mPFS compared to ≥3 lines (not reached vs. 23.6 months, <em>P</em>=0.0095). The 3-year OS rate was 94.0 % (95 % CI, 85.9–97.4). No serious adverse events with incidence >5 %.</div></div><div><h3>Conclusions</h3><div>With encouraging data on both PFS and OS, zimberelimab demonstrates ongoing efficacy and safety in treating R/R cHL, supporting zimberelimab as an effective treatment alternative for R/R cHL (NCT03655483).</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107633"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0